Skip to content

PAR-25-265 Newborn Screening R01 Eligibility

Updated 6 official sources

Quick Answer: PAR-25-265 is an NIH R01 for newborn screening and therapy research tied to screenable disorders.

Full answer and how we checked it

It is clinical trial optional, can support up to 5 years when justified, and should be compared with the companion PAR-25-266 R21 when the project is still exploratory. The 2026 decision turns on 7 checks.

Who this is for: Newborn screening researchers, pediatric genetics teams, therapy-development groups, diagnostic assay teams, state newborn-screening partners, and sponsored-research offices deciding whether PAR-25-265 is the right R01 route.

Data note: This guide uses NIH PAR-25-265, the companion NIH PAR-25-266 R21, Grants.gov listing 357485, NIH clinical-trial policy, and Grantsights award-data signals checked on June 2, 2026.

In this guide

PAR-25-265 isn't a generic pediatric R01. According to NIH PAR-25-265 (opens in a new tab), the NOFO encourages research relevant to novel screening approaches and therapeutic interventions for conditions where newborn screening has already been implemented, as well as serious genetic conditions that could benefit from early detection.

This is the kind of R01 where teams often choose the mechanism too soon. A promising newborn screening idea can be real science and still need an R21, pilot award, or assay-development step before it is ready for a 5-year R01.

Use this guide with the live NIH Newborn Screening and Therapies R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, best NIH grants for researchers, what is a NOFO, and the Grantsights grant database.

June 2026 Source Check

6 official-source checks should happen before a team treats PAR-25-265 as the right R01. NIH lists PAR-25-265 as an NICHD R01, clinical trial optional, with companion R21 PAR-25-266, application budgets that are not limited but must match project needs, and a maximum project period of 5 years. NIH standard due dates run through the November 17, 2027 expiration date; the last cycles listed are October 5, 2027 for new applications and November 5, 2027 for renewal, resubmission, and revision applications.

The source page also narrows the science. The project should develop screening approaches or therapy work for disorders already in newborn screening, or serious genetic conditions where early detection could matter soon. NIH says applicants proposing clinical trials or interventional studies in humans are strongly encouraged to contact scientific or research staff before submitting.

Source checkWhat to verify before writing
Trial statusClinical-trial optional does not remove trial-classification work
Mechanism fitR01 scale is justified versus companion R21 PAR-25-266
Screening pathCondition, assay, sample, follow-up, or state-screening workflow is clear
Therapy linkEarly detection changes treatment timing, outcome, or care decisions
Budget5-year scope and every budget year justified by project need
Data planDMS, human subjects, privacy, and genomic or rare-disease data handling are ready

The key routing question is not whether newborn screening is important. It is whether this specific project is R01-ready, correctly classified, and tied to a real early-detection pathway.

Get grant deadline alerts by email

About once a week, we email a short list of open grant calls with real deadlines from different funders. It isn't limited to the programs in this guide.

No spam. Unsubscribe anytime.

6 PAR-25-265 Eligibility Stop Checks

6 stop checks decide whether the R01 route fits before a 5 year project is planned. The applicant can be many organization types, but the project must fit newborn screening, therapy, mechanism scale, and clinical-trial status.

Stop checkStrong R01 signalRed flag
Screening fitCondition is in or near newborn screening useGeneral pediatric disorder without screening path
Therapy fitEarly detection changes treatment or outcomesTherapy question unrelated to screening
Mechanism scaleR01-level scope and evidence basePilot idea better suited to R21
Clinical-trial statusTrial classification is explicitTrial status is ambiguous
Public-health pathState screening or implementation relevance is clearNo screening-system connection
Review readinessAssay, condition, cohort, or therapy plan is specificBroad discovery with no near-term route

The first decision is not whether newborn screening matters. It does. The first decision is whether this project belongs in PAR-25-265, the companion R21, or another NIH path.

Don't treat that as a small routing detail. The wrong mechanism can waste a strong idea before reviewers ever reach the science.

5 Funding, Timing, and Mechanism Rules

5 public rules should be visible before drafting. NIH lists PAR-25-265 as an R01 clinical trial optional NOFO. The last new-application due date is October 5, 2027. The R01 path can support up to 5 years when scope and budget justify it.

RuleSource-backed read
Funding numberPAR-25-265
MechanismR01 research project grant
Clinical trial statusOptional
Companion routePAR-25-266 R21
Last due datesOctober 5, 2027 (new); November 5, 2027 (renewal, resubmission, revision)

According to NIH, clinical trial optional means the applicant must decide whether the project meets the NIH clinical-trial definition and use the correct application package and forms. According to USAspending.gov (opens in a new tab) data, the connected assistance listing (93.865) had about $1.24B in FY2024 obligations across 5,330 awards active that year.

5 R01 Versus R21 Route Choices

5 route choices matter within 21 days because NIH also lists a companion R21. PAR-25-265 fits larger, R01-ready projects. PAR-25-266 fits exploratory or developmental work that needs pilot data, feasibility testing, or early method development.

RouteBetter first read when...Why
PAR-25-265 R01Project has enough evidence for a larger multi-year studyR01 scale fits
PAR-25-266 R21The idea is exploratory or pilot-stageSmaller mechanism fits
Parent R01Newborn screening is adjacent but not centralBroader NIH route may fit
SBIR/STTRCompany-led assay or product development is centralSmall-business route may fit
Foundation or pilot fundsReadiness data is missingPrep funding may come first

For broader mechanism choice, use NIH R01 R21 R03 K awards comparison.

What NIH Doesn't Tell You

4 hidden readiness questions decide whether this belongs under PAR-25-265. NIH gives the source rules, but it does not decide whether the idea is ready.

First, NIH does not make every pediatric genetics project a newborn screening project. The screening system connection should be clear.

Second, NIH does not make clinical-trial optional a shortcut. If participants are assigned to an intervention, or if a therapy is prospectively tested, the team must handle clinical-trial requirements from the start.

Third, NIH does not make R01 the default. If the screening approach or therapy evidence is still thin, a 2-year R21 may be stronger than a stretched R01.

Fourth, NIH does not remove implementation reality. Newborn screening research often depends on sample access, state screening partners, clinical follow-up, confirmatory testing, family communication, and ethical handling of rare-disease results.

6 Real-World PAR-25-265 Scenarios

6 scenarios show where the route fits over 5 years of research. One team developing a validated screening approach for a condition with a clear early-treatment window may fit. One team with a broad gene-discovery idea and no screening route may need another mechanism.

ScenarioBetter routeWhy
Multi-year assay validation with state partnerPAR-25-265 R01Screening path and scale fit
Early biomarker idea with little dataPAR-25-266 R21Pilot-stage work fits
Therapy study tied to early detectionPAR-25-265 possibleScreening changes treatment window
Company-led diagnostic productSBIR/STTR or partner routeCommercial path may matter
General rare-disease biologyParent R01 or institute routeScreening fit may be weak
Small feasibility datasetPilot or R21R01 may be premature

For example, a research group with a state screening partnership, assay data, and outcome logic might be ready for the R01. A group with a promising biomarker but no specimen flow or follow-up plan should probably build feasibility first.

7 Draft Checks to Run First

7 checks should happen before writing. They save the team from forcing a pediatric project into a newborn screening mechanism.

  1. Confirm PAR-25-265 is still active and matches the deadline plan.
  2. State whether the project is a clinical trial.
  3. Compare the R01 with PAR-25-266 R21.
  4. Map the screening condition, technology, or therapy to a real early-detection pathway.
  5. Identify sample, data, state-screening, or clinical follow-up partners.
  6. Check that any budget year at $500,000 or more in direct costs is justified line by line. NIH dropped the pre-submission contact requirement for these budgets in NOT-OD-26-019 (opens in a new tab), even though the PAR-25-265 text still carries the old language.
  7. Contact NIH program staff if mechanism fit or clinical-trial status is unclear.

According to NIH, the application must follow the Research instructions in the How to Apply Application Guide unless the NOFO says otherwise. That matters because mechanism choice, clinical-trial status, human-subjects forms, and data sharing can all change the submission package.

7 Evidence Assets That Make This R01 Stronger

7 evidence assets move this from a good idea to a credible R01. The strongest applications will not ask reviewers to believe that newborn screening is valuable in general. They will show why this condition, assay, therapy, cohort, and care pathway are ready for a multi-year NIH project.

First, show the screening gap with enough detail for a reviewer to see the system problem. That might mean false positives, missed cases, slow confirmatory testing, uneven access, lack of follow-up data, weak assay performance, or uncertainty about which infants benefit from early treatment.

Second, explain why early detection changes the outcome. According to NIH, PAR-25-265 is meant for conditions where newborn screening is already in use or where early detection could support future screening. A therapy-only project that would have the same value after symptoms appear is weaker than a project where screening timing changes treatment, prognosis, or care planning.

Third, prove the team can get the right specimens, data, and follow-up. Newborn screening work can fail because dried blood spots, confirmatory testing, genetic data, treatment records, or long-term outcomes cannot be linked cleanly. The application should not treat data access as a footnote.

Fourth, show the assay or therapy evidence that makes the R01 scale honest. If the project still needs basic feasibility, skip the R01 and use PAR-25-266 or another prep route. Reviewers will usually prefer a smaller clean project over a large project built on uncertain readiness.

Fifth, include a clinical-trial decision memo before the team writes the research strategy. According to NIH, PAR-25-265 accepts applications that do or do not propose clinical trials. That flexibility is useful, but it also means the team must classify the work correctly at the start.

Sixth, connect the project to families and screening programs. A university team with a state laboratory partner, a validated second-tier assay, and a follow-up clinic could explain exactly how infants move from a screen to confirmation to therapy. That kind of workflow is more persuasive than a generic claim that the condition is rare and serious.

Seventh, include a data sharing plan that matches the kind of data produced. According to NIH, applications under this NOFO must include a Data Management and Sharing Plan. If the study generates human genomic data, family-level information, or rare-disease records, the plan should address privacy, repositories, timing, and who can reasonably reuse the data.

21-Day Newborn Screening R01 Routing Plan

21 days is enough to decide whether the team should draft. Days 1 through 3 should confirm source status, target receipt date, clinical-trial status, and mechanism fit.

Days 4 through 7 should test screening relevance. The project should explain how early detection changes screening, diagnosis, therapy timing, or outcome interpretation.

Days 8 through 12 should compare R01 and R21. If the assay, therapy, cohort, or data access is still fragile, the R21 may be the better first step.

Days 13 through 16 should build the partner map. State labs, clinical genetics groups, newborn screening programs, biostatistics, ethics, and family engagement may all matter.

Days 17 through 21 should run budget and submission checks. Since December 3, 2025, NIH no longer requires applicants requesting $500,000 or more in direct costs in any year to contact the institute before submitting (NOT-OD-26-019 (opens in a new tab)). Talking to the NICHD program officer about a large budget is still optional and often useful.

6 Reviewer-Risk Signals to Fix

6 risk signals should be fixed before submission. First, the project should not read like general rare-disease science with a screening label.

Second, the clinical-trial status should be explicit. Trial uncertainty can damage the application before peer review.

Third, the screening technology or therapy plan should connect to patient or public-health value.

Fourth, the project should not overpromise state implementation if partners are not committed.

Fifth, the budget should match the mechanism. R01 scale needs R01-level evidence and management capacity.

Sixth, the application should show why the work belongs under this newborn screening route instead of parent R01, R21, SBIR/STTR, or foundation funding.

6 Budget And Scope Questions Before Submission

6 budget questions should be answered before the institutional routing deadline. According to NIH, PAR-25-265 application budgets are not limited but must reflect the real needs of the proposed project, and the maximum project period is 5 years.

The first question is whether each budget year maps to a real scientific workstream. A 5 year budget should not just spread the same staff across a long period. It should show assay validation, cohort work, therapy testing, data analysis, or follow-up work in a sequence that makes sense.

The second question is whether the project needs state newborn-screening partners, clinical sites, biostatistics, ethics, or family engagement costs. If those roles matter, they should appear in the budget and in the work plan.

The third question is whether any subcontract has a clear reason to exist. A state laboratory, follow-up clinic, sequencing core, or outcomes team may be worth funding. A vague partner role is weaker.

The fourth question is whether clinical-trial needs are priced correctly. If the project is a trial, the budget has to reflect monitoring, recruitment, safety, data systems, and trial administration. If it is not a trial, the application should not accidentally create trial-like costs and language.

The fifth question is whether data sharing and privacy work are funded. Rare-disease newborn data can be sensitive, and reuse plans often require more than a paragraph.

The sixth question is whether the R21 would make the budget cleaner. Avoid a stretched R01 when a 2 year R21 would prove the assay, partner workflow, or therapy signal first.

5 Applicant Types and Best Next Move

5 applicant types commonly ask about PAR-25-265.

Applicant typeBest next moveWhy
Assay-development research teamTest R01 versus R21 readinessMechanism scale matters
Therapy-development teamConfirm early-detection linkTherapy must connect to screening
State screening partnerDefine sample and follow-up roleImplementation path matters
Rare-disease biology teamCompare parent R01Screening fit may be weak
Small business teamCompare SBIR/STTRProduct path may differ

The best answer is: use PAR-25-265 when the project is screening-connected, R01-ready, correctly classified for clinical-trial status, and ready for multi-year execution.

7 Newborn Screening R01 Route Checks Updated June 2, 2026

6 checks separate official source facts from project-specific choices. First, verify PAR-25-265 source status and the next NIH receipt date. Second, classify the project as trial or non-trial before forms and budget work begin. Third, compare the R01 against companion R21 PAR-25-266 before assuming 5 years is the right scale.

Fourth, prove the screening pathway: condition, assay, sample source, follow-up, state partner, or clinical handoff. Fifth, show why early detection changes therapy timing or outcome. Sixth, price state-screening, clinical, ethics, data, and family-facing work honestly, including any year at $500,000 or more in direct costs.

Checked on June 2, 2026 against PAR-25-265 (opens in a new tab), PAR-25-266 (opens in a new tab), the Grants.gov listing (opens in a new tab), NIH clinical trial policy (opens in a new tab), and USASpending.gov (opens in a new tab).

CheckPublic answer
EligibilityConfirm the applicant, institution, and route rules for PAR-25-265 newborn screening R01 eligibility.
Source statusVerify the official listing, notices, due date, and expiration status.
BudgetCheck award size, cost limits, match, or budget logic when the source provides it.
EvidenceName the data, preliminary work, partner role, or implementation proof needed.
Bad fitStop if the project belongs in a nearby NIH or federal route.
Review criteriaTie the first page to significance, approach, team, environment, and source-specific criteria.
Next actionDecide whether to draft, ask a program contact, redirect, or move to a nearby route.

Final public checklist

  • Confirm whether R01 is the right route or whether a nearby program fits better.
  • Check budget, partner, match, or data-readiness constraints.

Sources

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Federal Program Records to Compare

Use these current program records to check eligibility, award history, deadlines, and past winners before your team commits writing time.

Frequently Asked Questions

What does PAR-25-265 fund?

NIH says the NOFO supports research on novel screening approaches and therapeutic interventions for conditions already in newborn screening or conditions that may benefit from early detection.

Are clinical trials allowed?

Yes. PAR-25-265 is clinical trial optional, so applicants must correctly classify whether the work includes a clinical trial.

What is the companion R21?

NIH lists PAR-25-266 as the companion R21 for exploratory or developmental newborn screening and therapy projects.

What is the maximum project period?

The R01 mechanism can support projects up to 5 years when the scope justifies that period.

Who should use the R21 instead?

Use the R21 when the project is exploratory, pilot-stage, or generating data before a larger R01.

Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.